Patients with CSF sample (n=43) | ||
---|---|---|
Demographic characteristics | ||
Age in years (median, [IQR]) | 61 | [50–69] |
Sex (n, % of males) | 27 | 62.8% |
Mortality | ||
Death at 6 months (n, %) | 14 | 32.6% |
Morbidity | ||
Glasgow Outcome Scale, GOS (n, %) | ||
Good recovery to moderate disability (1–3) | 21 | 55.3% |
Severe disability and death (4–5) | 17 | 44.7% |
Other characteristics | ||
MacCabe score (n, %) | ||
No fatal disease (0) | 34 | 79.1% |
Death in the next 1 or 5 years (1–2) | 8 | 19.0% |
Knaus score (n, %) | ||
Normal health status (A) | 23 | 54.8% |
Moderate limitation to bedridden patients (B-D) | 19 | 45.2% |
Time to acyclovir initiation in days (median, [IQR]) | 1 | [0–2] |
Alcohol consumption (n, %) | 6 | 14.0% |
Body temperature (°C) (median, [IQR]) | 38.9 | [38.4–39.5] |
GCS score (median, [IQR]) | 14 | [12–15] |
Leukocyte count (cells/μL) (median, [IQR]) | 50 | [8–142] |
Lymphocyte percentage of white cells (median, [IQR]) | 80.5 | [10–96] |
Time to lumbar puncture (days) (median, [IQR]) | 1 | [0–1] |
HSV load (log10 copies/μL) (median, [IQR]) | 2.0 | 1.2–2.6 |